Post Number: 4
|Posted on Monday, March 07, 2011 - 07:23 pm: ||
Please see below several new facts regarding AlloMap:
In April 2010 the New England Journal of Medicine published an article by Dr. Pham presenting the results of a study comparing outcomes for heart transplant recipients managed with AlloMap versus outcomes for patients managed with endomyocardial biopsies. It concluded that “a strategy of monitoring for rejection that involved gene-expression profiling, as compared with routine biopsies, was not associated with an increased risk of serious adverse outcomes and resulted in the performance of significantly fewer biopsies”.
In August 2010 the International Society for Heart and Lung Transplantation published its first-ever clinical guidelines. The document states that “Gene Expression Profiling (Allomap) can be used to rule out the presence of ACR* of grade 2R or greater in appropriate low-risk patients, between 6 months and 5 years after HT**.”
In October 2010 the California Technical Assessment Forum reviewed AlloMap and stated; “It is recommended that the use of gene expression profiling meets Technology Assessment Criterion 1 through 5 for safety, effectiveness and improvement in health outcomes when used to manage heart transplant patients at least one year post-transplant”.
In February 2011 Aetna posted its policy regarding AlloMap: “Aetna considers the AlloMap gene expression profile medically necessary for monitoring rejection in heart transplant recipients more than one year post heart transplant”.
As of March 2011 the AlloMap test has been performed by 75% of all heart transplant centers on more than 8,000 heart transplant recipients.
*acute cellular rejection